100+ ab humanization projects
10+ affinity maturation projects delivered
Immunogenicity can potentially lead to reduced efficacy through rapid clearance or neutralization of the drug, or toxicity due to cross-reaction with proteins in the body, which can have catastrophic consequences for the patient. Antibody humanization can reduce the immunogenicity of monoclonal antibodies derived from xenogeneic sources and to improve their activation of the human immune system by replacing non-human antibody frameworks with human ones. It is a very important step in
therapeutic antibody discovery process.
In some cases that the obtained leads have relative low affinity (such as phage library campaign), or the final application needs extremely high affinity, affinity maturation is required to preserve the epitope specificity and functional activity of the antibody and boost potency to the desired level. In addition, it can be useful to remove potential modification sites for improved developability.
As a one-stop supplier for therapeutic antibody discovery and development, GenScript is proud to offer integrated antibody humanization and affinity maturation service. Combining in silico CDR-grafting, structure-based back mutation, and, supported by our patented
FASEBA(Fast Screening for Expression, Biophysical-properties and Affinity) screening,
Surface Plasmon Resonance platform and
functional assay platform, the antibody humanization service is offered at GenScript to generate humanized antibody maintaining the affinity and specificity of parental antibody and optimized activity, productivity and thermostability. Seamlessly integrated with humanization, the affinity maturation service will continuously improve the affinity by 10 to 50 folds.
When using fluorophores, individually or in a multiplex format, it is important to pay attention to a few technical features including: